TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$152.03 MLiabilities$774.84 MNon-current liabilities$622.81 MCurrent assets$615.14 MAssets$799.36 MEquity$24.52 MGross equity(calculated)$1.57 BNon-current assets$184.22 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable debt securities, at fair valueCash and cash equivalentsAccounts receivable, netPrepaid expenses and other current assetsInventoryIntangible assets, netLong-term inventoryOperating lease right of use assetsOther assetsProperty and equipment, netAccrued expensesAccounts payableOperating lease liabilities, current portionOther current liabilitiesConvertible debtOther non-current liabilitiesOperating lease liabilities, less current portionAdditional paid-in capitalCommon stock $0.0001 par value; 200,000,000 shares authorized; 94,174,767 and 90,922,868 issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive lossAccrued expensesAccrued expenses$136.27 MCurrent liabilitiesCurrent liabilities$152.03 MAccounts payableAccounts payable$7.50 MLiabilitiesLiabilities$774.84 MOperating lease liabilities, current portionOperating lease liabilities, current portion$6.16 MOther current liabilitiesOther current liabilities$2.10 MNon-current liabilitiesNon-current liabilities$622.81 MConvertible debtConvertible debt$602.78 MCurrent assetsCurrent assets$615.14 MMarketable debt securities, at fair valueMarketable debt securities, at fair value$371.44 MAssetsAssets$799.36 MEquityEquity$24.52 MOther non-current liabilitiesOther non-current liabilities$12.07 MCash and cash equivalentsCash and cash equivalents$117.74 MOperating lease liabilities, less current portionOperating lease liabilities, less current portion$7.96 MGross equity (calculated)Gross equity(calculated)$1.57 BAccounts receivable, netAccounts receivable, net$80.64 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$37.49 MInventoryInventory$7.84 MIntangible assets, netIntangible assets, net$131.52 MNon-current assetsNon-current assets$184.22 MLong-term inventoryLong-term inventory$32.21 MOperating lease right of use assetsOperating lease right of use assets$8.75 MOther assetsOther assets$8.51 MAdditional paid-in capitalAdditional paid-in capital$1.57 BProperty and equipment, netProperty and equipment, net$3.23 MCommon stock $0.0001 par value; 200,000,000 shares authorized; 94,174,767 and 90,922,868 issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock $0.0001 par value$9.00 KAccumulated deficitAccumulated deficit−$1.54 BAccumulated other comprehensive lossAccumulated other comprehensive loss−$1.12 M
Chart details

TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
799,360,000 US dollars
Current assets
615,141,000 US dollars
Non-current assets
184,219,000 US dollars
Liabilities
774,838,000 US dollars
Current liabilities
152,025,000 US dollars
Non-current liabilities
622,813,000 US dollars
Equity
24,522,000 US dollars
Marketable debt securities, at fair value
371,442,000 US dollars
Cash and cash equivalents
117,735,000 US dollars
Accounts receivable, net
80,636,000 US dollars
Prepaid expenses and other current assets
37,493,000 US dollars
Inventory
7,835,000 US dollars
Intangible assets, net
131,518,000 US dollars
Long-term inventory
32,214,000 US dollars
Operating lease right of use assets
8,745,000 US dollars
Other assets
8,511,000 US dollars
Property and equipment, net
3,231,000 US dollars
Accrued expenses
136,267,000 US dollars
Accounts payable
7,495,000 US dollars
Operating lease liabilities, current portion
6,163,000 US dollars
Other current liabilities
2,100,000 US dollars
Convertible debt
602,781,000 US dollars
Other non-current liabilities
12,071,000 US dollars
Operating lease liabilities, less current portion
7,961,000 US dollars
Additional paid-in capital
1,570,242,000 US dollars
Common stock $0.0001 par value; 200,000,000 shares authorized; 94,174,767 and 90,922,868 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
9,000 US dollars
Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 1,544,612,000 US dollars
Accumulated other comprehensive loss
negative 1,117,000 US dollars
Gross equity (calculated)
1,570,251,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!